Crizanlizumab

Generic Name: Crizanlizumab

Brand Names: Adakveo

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1690318-25-2

Unique Ingredient Identifier: L7451S9126

Background: Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the formation of abnormal, sickl...

Indication: Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crisis in patients with sickle cell diseases who are ≥16 years old.

Associated Conditions: Vaso-occlusive Crisis

Associated Therapies: -

Clinical Trials

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Phase 3

Recruiting

Conditions: Sickle Cell Disease

Interventions: Biological: Crizanlizumab
Drug: Placebo

First Posted Date: 2024-06-03

Last Posted Date: 2024-11-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 315

Registration Number: NCT06439082

Locations: 🇺🇸
WCG Sonar Clinical Research, Riverdale, Georgia, United States

Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia

Phase 1

Not yet recruiting

Conditions: Sickle Cell Disease

Interventions: Other: control
Drug: Crizanlizumab

First Posted Date: 2022-07-22

Last Posted Date: 2023-08-30

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 30

Registration Number: NCT05469828

An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients

Phase 4

Completed

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: crizanlizumab

First Posted Date: 2020-12-10

Last Posted Date: 2024-04-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT04662931

Locations: 🇮🇳
Novartis Investigative Site, Guwahati, India

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Phase 4

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Crizanlizumab

First Posted Date: 2020-12-08

Last Posted Date: 2024-10-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT04657822

Locations: 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸
Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸
Augusta University Georgia Patient Treatment, Augusta, Georgia, United States

and more 5 locations

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

Phase 2

Active, not recruiting

Conditions: RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy

Interventions: Drug: Crizanlizumab

First Posted Date: 2020-11-02

Last Posted Date: 2023-02-14

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 20

Registration Number: NCT04611880

Locations: 🇺🇸
Andria Ford, Saint Louis, Missouri, United States
🇺🇸
Perelman School of Medicine; University of Pennsylvania, Philadelphia, Pennsylvania, United States

Crizanlizumab for Treating COVID-19 Vasculopathy

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Crizanlizumab
Other: 0.9% saline

First Posted Date: 2020-06-17

Last Posted Date: 2021-11-09

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 54

Registration Number: NCT04435184

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Phase 1

Completed

Conditions: Myelofibrosis

Interventions: Drug: Ruxolitinib
Drug: Crizanlizumab
Drug: Sabatolimab
Drug: Siremadlin
Drug: NIS793
Drug: Rineterkib

First Posted Date: 2019-09-20

Last Posted Date: 2024-12-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT04097821

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Phase 2

Completed

Conditions: Priapism

Interventions: Drug: crizanlizumab

First Posted Date: 2019-05-06

Last Posted Date: 2024-04-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT03938454

Locations: 🇺🇸
Childrens Hospital Boston, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh ., Pittsburgh, Pennsylvania, United States
🇺🇸
Foundation for Sickle Cell Disease Research, Hollywood, Florida, United States

and more 10 locations

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients

Conditions: Sickle Cell Disease

First Posted Date: 2018-10-25

Last Posted Date: 2024-10-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03720626

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: Crizanlizumab

First Posted Date: 2018-03-23

Last Posted Date: 2024-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT03474965

Locations: 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸
Univ of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸
Joe DiMaggio Childrens Hospital, Hollywood, Florida, United States

and more 10 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy